再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

未开盘 06-16 16:08:14

13.960

+0.250

+1.82%

最高13.990	最低13.480	成交量1,233万
今开13.860	昨收13.710	日振幅3.72%
总市值158.31亿	流通市值158.31亿	总股本11.34亿
成交额1.70亿	换手率1.09%	流通股本11.34亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":13.96,"timestamp":1781597294010,"preClose":13.71,"halted":0,"volume":12330300,"delay":0,"changeRate":0.01823486506199854,"floatShares":1134000000,"shares":1134000000,"eps":-1.2553519813884995,"marketStatus":"未开盘","change":0.25,"latestTime":"06-16 16:08:14","open":13.86,"high":13.99,"low":13.48,"amount":169625197,"amplitude":0.037199,"askPrice":13.97,"askSize":1600,"bidPrice":13.96,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":-1.2661146925890823,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781659800000},"marketStatusCode":0,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":13.71,"openAndCloseTimeList":[[1781573400000,1781582400000],[1781586000000,1781596800000]],"volumeRatio":0.7890194205443508,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688","defaultTab":"news","newsList":[{"id":"1136022914","title":"异动解读｜再鼎医药盘中上涨5.57%，精神分裂创新药上市叠加宫颈癌新药获批双重利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1136022914","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136022914?lang=zh_cn&edition=full","pubTime":"2026-06-10 15:08","pubTimestamp":1781075339,"startTime":"0","endTime":"0","summary":"6月10日，再鼎医药盘中上涨5.57%，报13.26港元/股，成交额1.76亿港元。消息面上，公司首个神经领域产品呫诺美林曲司氯铵胶囊（凯捷乐）于6月9日正式发货，已在全国30余个城市、近50家医院供药，并在首都医科大学附属北京安定医院开出全国首张处方。此外，国家药监局已批准公司宫颈癌新药缇乐（注射用维替索妥尤单抗）的上市许可申请，用于治疗复发或转移性宫颈癌成人患者，该获批基于全球3期innovaTV 301临床研究中展现的显著总生存获益。双重产品落地利好提振市场情绪，推动股价走强。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642144385","title":"港股异动 | 再鼎医药(09688)涨超4% 精神分裂创新药凯捷乐®上市 宫颈癌新药在华获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2642144385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642144385?lang=zh_cn&edition=full","pubTime":"2026-06-10 14:46","pubTimestamp":1781074008,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药涨超4%，截至发稿，涨4.06%，报13.07港元，成交额1.56亿港元。当天，该药在首都医科大学附属北京安定医院开出全国首张处方，并于同日惠及全国30余个城市、近50家医院的精神分裂症患者。此外，再鼎医药日前宣布，国家药品监督管理局已批准缇乐的生物制品上市许可申请，用于治疗化疗期间或之后出现进展的复发或转移性宫颈癌成人患者。维替索妥尤单抗在全球3期innovaTV301临床研究中展现出了显著的统计学意义总生存获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4526","06978","159992","BK1574","BK1161","BK4548","09688","BK1588","BK4531","BK4585","IPOS","LU2488822045.USD","BK4139","BK4588","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130204634","title":"再鼎医药Tivdak®（注射用替索妥玛维度汀）获中国国家药监局批准，用于治疗复发或转移性宫颈癌成年患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1130204634","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130204634?lang=zh_cn&edition=full","pubTime":"2026-06-09 08:34","pubTimestamp":1780965261,"startTime":"0","endTime":"0","summary":"再鼎医药宣布，其创新药物Tivdak已获得中国国家药品监督管理局的上市批准。该药物适用于治疗既往接受过系统治疗后出现疾病进展的复发或转移性宫颈癌成年患者。这一批准标志着再鼎医药在肿瘤治疗领域取得了重要进展，为国内面临治疗困境的宫颈癌患者提供了新的治疗选择。获得监管批准是药物商业化进程中的关键一步。预计此次获批将有望拓展再鼎医药的产品组合，并对其未来的营收增长产生积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1161","09688","BK1574","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125914549","title":"异动解读｜再鼎医药盘中下跌5.05%，基本面承压叠加生物科技板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1125914549","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125914549?lang=zh_cn&edition=full","pubTime":"2026-06-05 14:20","pubTimestamp":1780640406,"startTime":"0","endTime":"0","summary":"6月5日，再鼎医药盘中下跌5.05%，报12.59港元/股，成交额1.31亿港元。消息面上，公司此前披露一季度总营收同比下降6%至9960万美元，同时总裁兼首席运营官Josh Smiley离职引发市场对管理层稳定性的担忧。股价近一个月累计跌幅近20%，持续承压。当日生物科技板块整体走弱，康方生物跌4.17%、百济神州跌2.92%、三生制药跌2.38%，板块情绪偏弱进一步放大个股跌幅。大摩此前给予再鼎医药\"增持\"评级，目标价19港元，当前股价较目标价仍有较大折价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151048567","title":"再鼎医药5月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1151048567","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151048567?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:07","pubTimestamp":1780571227,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司于2026年6月4日发布截至2026年5月31日的股份变动月报。公告显示，报告期内公司注册股本与已发行股份数维持稳定，未发生新增发行、回购或注销股份的情况。截至本月末，公司已发行股本仍为1,134,128,030股，股本结构和公眾持股量未发生实质变化。公司确认其所有股份及库存股的发行、出售或转让已符合香港联交所相关上市规则及法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640020489","title":"再鼎医药(09688)授出5000份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2640020489","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640020489?lang=zh_cn&edition=full","pubTime":"2026-06-03 21:25","pubTimestamp":1780493128,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，公司于2026年6月1日(美国东部时间)根据2024年股权激励计划授出5000份受限制股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4588","ZLAB","BK1161","BK4526","BK1574","BK4548","BK4585","09688","LU2488822045.USD","BK4139","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146642225","title":"异动解读｜再鼎医药盘中上涨5.51%，ASCO年会开幕催化创新药板块反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1146642225","media":"行情直击","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146642225?lang=zh_cn&edition=full","pubTime":"2026-05-29 09:52","pubTimestamp":1780019525,"startTime":"0","endTime":"0","summary":"5月29日，再鼎医药盘中上涨5.51%，报14.13港元/股，成交额5221.05万港元。消息面上，ASCO年会于5月29日在芝加哥正式开幕，本届大会中国学者入选口头报告达95项创历史新高，12家中国创新药企13项研究入选最新突破摘要，带动生物科技板块整体走强。再鼎医药此前因总裁兼首席运营官Josh Smiley离职及一季度总营收同比下降6%至9960万美元，5月28日曾下跌5.03%。本次反弹与创新药板块集体受ASCO催化密切相关，同板块信达生物涨6.88%、康方生物涨1.0%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113351863","title":"异动解读｜再鼎医药盘中下跌5.03%，总裁离职叠加核心产品收入骤降","url":"https://stock-news.laohu8.com/highlight/detail?id=1113351863","media":"行情直击","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113351863?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:35","pubTimestamp":1779953756,"startTime":"0","endTime":"0","summary":"5月28日，再鼎医药盘中下跌5.03%，报13.6港元/股，成交额1.22亿港元。消息面上，公司于5月22日公告，董事会决定Josh Smiley不再担任总裁兼首席运营官，自5月18日起生效。此前公司披露一季度总营收9960万美元，同比下降6%；核心产品则乐收入降幅接近四成，净亏损5100万美元。市场将本次高管非自愿离职与一季度业绩下滑直接关联，短期内经营层面不确定性加剧。同日生物科技板块整体承压，信达生物跌5.07%、康方生物跌4.69%、三生制药跌7.61%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638582374","title":"547万美元年薪总裁匆匆离场，再鼎医药发生了什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2638582374","media":"华夏时报网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638582374?lang=zh_cn&edition=full","pubTime":"2026-05-25 11:44","pubTimestamp":1779680649,"startTime":"0","endTime":"0","summary":"5月22日，再鼎医药（09688.HK）一则公告引发市场高度关注——公司总裁兼首席运营官JoshSmiley将不再担任现任职务，自5月18日起生效，最后任职日期为5月22日。颇为耐人寻味的是，从董事会作出决定到这位“二把手”正式离场，仅间隔4天。公告同时提及，Smiley需签署一份“常规的解除协议”后方可获得遣散补偿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605253747976870.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605253747976870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4548","09688","BK4526","BK4585","BK4588","BK1161","ZLAB","LU2488822045.USD","BK4531","BK1588","BK4139","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637653033","title":"再鼎医药(09688)：Josh Smiley不再担任公司总裁兼首席运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2637653033","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637653033?lang=zh_cn&edition=full","pubTime":"2026-05-22 08:25","pubTimestamp":1779409550,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于2026年5月21日(美国东部时间)╱2026年5月22日(上海及香港时间)向美国证券交易委员会(SEC)递交了一份表格8-K，有关本公司董事会决定 Josh Smiley 先生将不再担任本公司总裁兼首席运营官，自2026年5月18 日起生效，其在本公司的最后任职日期为2026年5月22日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"再鼎医药(09688)：Josh Smiley不再担任公司总裁兼首席运营官","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1588","BK4548","ZLAB","BK4585","BK4526","09688","BK4531","BK4139","BK1161","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287792.SGD","BK1589","AGIX","LU0561508036.HKD","LU1226288170.HKD","LU0456827905.SGD","01877","06160","02616","LU1152091754.HKD","IE00B031HY20.USD","LU0456846285.SGD","AIPO","LU0516422952.EUR","LU0634319403.HKD","LU0072913022.USD","01177","06185","02142","LU1880383366.USD","BK1583","LU0140636845.USD","159992","01093","BK1588","LU0348827113.USD","LU1303224171.USD","LU2097828631.EUR","09995","CHAT","LU0326950275.SGD","06978","LU0572944931.SGD","LU0856984785.SGD","01801","BK1161","02269","LU1993786604.SGD","LU0348767384.USD","SG9999002562.SGD","LU1719994722.HKD","ARTY","LU0067412154.USD","LU1960683339.HKD","09926","LU1152091168.USD","LU0417516738.SGD","LU0315179316.USD","IE00BPRC5H50.USD","09688"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1303224171.USD","IE00B543WZ88.USD","LU1152091754.HKD","LU1969619763.USD","02616","LU2097828631.EUR","LU2097828474.EUR","LU0359202008.SGD","01877","BK1141","BK1161","BK1588","01093","09926","LU0348827113.USD","LU0516423174.USD","LU1242518931.SGD","LU1993786604.SGD","LU0561508036.HKD","02269","06185","LU2399975544.HKD","BK1574","IE00B5MMRT66.SGD","LU1152091168.USD","IE00BZ08YT58.USD","LU2097828557.USD","IE00B0JY6N72.USD","601066","LU1226287875.USD","02142","LU1688375341.USD","IE00BZ08YR35.GBP","LU0039217434.USD","159992","LU0417516738.SGD","06978","06160","01801","LU0326950275.SGD","01177","SG9999002562.SGD","09688","LU0516422952.EUR","LU1242518857.USD","IE00BZ08YS42.EUR","LU0456827905.SGD","09995","LU0979878070.USD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635033220","title":"再鼎医药(ZLAB)逆市上涨1.52% zoci近日获美国FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2635033220","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635033220?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:40","pubTimestamp":1778856000,"startTime":"0","endTime":"0","summary":"金吾财讯 |再鼎医药 逆市上涨1.52%，最新报20.64美元，成交额774.69万美元。消息面上，再鼎医药官微日前宣布，美国食品药品监督管理局已授予具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。此外，高盛新近披露，已于5月8日以每股均价15.09港元场外增持再鼎医药545.57万股H股股份，价值约8,232.65万港元。增持后，高盛最新持股数目为7,070.61万股股份，好仓比例由5.75%升至6.23%。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/NWIzNTQyNTc0Mjc1MDI=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWIzNTQyNTc0Mjc1MDI=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300518","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK1588","BK1574","BK4548","BK4588","09688","LABU","ZLAB","BK4531","BK4526","BK1161","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635700344","title":"港股异动 | 再鼎医药(09688)尾盘涨超5% zoci获FDA快速通道资格认定 用于治疗肺外神经内分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2635700344","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635700344?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:50","pubTimestamp":1778831448,"startTime":"0","endTime":"0","summary":"再鼎医药(09688)尾盘涨超5%，截至发稿，涨4.89%，报16.1港元，成交额2.47亿港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260515/20260515155119_66712.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260515/20260515155119_66712.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4548","LU2488822045.USD","BK4588","ZLAB","BK4139","VXUS","BK4531","BK1588","BK1574","BK4526","BK4585","LABU","BK1161","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164907709","title":"异动解读 | 再鼎医药盘中大涨5.11%，核心ADC管线获FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1164907709","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164907709?lang=zh_cn&edition=full","pubTime":"2026-05-14 09:54","pubTimestamp":1778723682,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大涨5.11%，引起了市场的广泛关注。消息面上，再鼎医药近日宣布，美国FDA已授予其具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。快速通道资格有助于加速药物审评进程，体现FDA对该适应症未满足临床需求的认可。此外，公司于5月12日披露根据2024年股权激励计划授出13.68万份购股权及7.53万份受限制股份单位，涉及相关股份合计超212万股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06996","02256","03888","02126","01783","00772","03700","06186","06609","01357","02013","09699","02171","02197","02276","03692","00169","81024","01905","01951","02096","02172","06060","06160","00136","09858","01440","06049","00719","09626","01548","02252","01060","01952","01024","00013","09992","02306","09688","02192","01833","02618","00909","02158","02285","06660","06969","00762","09888","06963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634299314","title":"再鼎医药(09688)：授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2634299314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634299314?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:34","pubTimestamp":1778574847,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于授出日期根据2024年股权激励计划授出13.68万份购股权(以美国存托股份计)、7.53万份受限制股份单位(以美国存托股份计)。所授出购股权涉及的相关股份数目：1,368,190;所授出受限制股份单位涉及的相关股份数目：752,880。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4548","ZLAB","BK4588","BK4585","09688","BK4531","BK4526","BK1161","LU2488822045.USD","BK1588","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634250452","title":"港股异动 | 再鼎医药(09688)早盘涨超5% zoci获FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2634250452","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634250452?lang=zh_cn&edition=full","pubTime":"2026-05-12 10:55","pubTimestamp":1778554548,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药早盘涨超5%，截至发稿，涨2.38%，报15.49港元，成交额7370.89万港元。消息面上，5月11日，据再鼎医药官微消息，公司宣布，美国食品药品监督管理局已授予具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 再鼎医药(09688)早盘涨超5% zoci获FDA快速通道资格认定","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","ZLAB","BK1119","BK4531","BK1574","BK4526","BK4548","BK4139","BK4588","LU2488822045.USD","BK1161","09688","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285739","title":"再鼎医药(ZLAB)自研药物Zoci获美国FDA授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285739","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634285739?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:36","pubTimestamp":1778499399,"startTime":"0","endTime":"0","summary":"据悉，epNECs为侵袭性强、预后差的恶性肿瘤，全球约10万人患病，无获批靶向疗法与标准治疗方案，存在巨大未满足医疗需求。此前2025年5月，Zoci已获FDA快速通道资格，用于广泛期小细胞肺癌治疗。此外，2026年AACR年会公布的Ib/II期注册研究显示，Zoci用于多线治疗失败的epNEC患者，客观缓解率达38.2%，且安全性可控，仅中性粒细胞减少为唯一≥3级且多例出现的治疗相关不良反应。目前Zoci的epNEC临床项目正推进注册，已与药监部门沟通注册计划。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300251","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","09688","BK4139","LU2488822045.USD","BK4588","BK1161","BK1574","BK4548","BK4531","BK1588","ZLAB","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175506875","title":"再鼎医药DLL3靶向ADC药物Zoci获美国FDA快速通道资格，用于治疗肺外神经内分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1175506875","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175506875?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:04","pubTimestamp":1778497466,"startTime":"0","endTime":"0","summary":"再鼎医药旗下靶向DLL3的抗体偶联药物（ADC）Zocilurtatug Pelitecan（简称Zoci）已获得美国食品药品监督管理局（FDA）授予的快速通道资格，用于治疗肺外神经内分泌癌（Ep-NECs）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1574","09688","LU2488822045.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.1115},{"period":"1month","weight":-0.1324},{"period":"3month","weight":-0.0637},{"period":"6month","weight":0.0116},{"period":"1year","weight":-0.5678},{"period":"ytd","weight":0.0227}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":-0.0566},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.0394},{"period":"1year","weight":0.018},{"period":"ytd","weight":-0.0443}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.017355},{"month":2,"riseRate":0.666667,"avgChangeRate":0.068855},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.098942},{"month":4,"riseRate":0.666667,"avgChangeRate":0.061043},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.046017},{"month":6,"riseRate":0.5,"avgChangeRate":-0.010895},{"month":7,"riseRate":0.8,"avgChangeRate":0.065752},{"month":8,"riseRate":0.6,"avgChangeRate":-0.021717},{"month":9,"riseRate":0.4,"avgChangeRate":-0.054178},{"month":10,"riseRate":0.5,"avgChangeRate":-0.051338},{"month":11,"riseRate":0.5,"avgChangeRate":0.047251},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.024481}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}